Lucie Harpain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucie Harpain has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Sonja Radakovic
Department of Dermatology Medical University of Vienna Vienna Austria
4 shared publications Adrian Tanew
Private Practice Vienna Austria
2 shared publications- Adrian Tanew
Private Practice Vienna Austria
2 shared publications - Alessandra Handisurya
Department of Dermatology Medical University of Vienna Vienna Austria
2 shared publications - Julia Walochnik
Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
2 shared publications Sandra Osorio
Department of Dermatology Medical University of Vienna Vienna Austria
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Elsevier in JAAD Case Reports
Heinz-Lippmann disease: Not always a complication
- 26 October 2026
- Published by Elsevier in JAAD Case Reports
Open AccessHeinz-Lippmann disease: Not always a complication
- Open Access
- 8 September 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Systemic treatment of cutaneous leishmaniasis: A systematic review and meta‐analysis
Background: Cutaneous leishmaniasis (CL) is increasingly reported in previously non‐endemic European countries. Although often self‐limiting or amenable to topical therapy, systemic treatment is indicated in specific situations. Evidence guiding systemic therapies remains limited and heterogeneous. Objectives: This systematic review and meta‐analysis aimed to synthesize available evidence on systemic treatment regimens for CL. Methods: MEDLINE/PubMed and Embase were searched for clinically and/or parasitologically confirmed CL receiving systemic monotherapy with meglumine antimoniate (MA), miltefosine, azoles, pentamidine, or liposomal amphotericin B (L‐AmB) until February 2026. Primary outcome was clinical cure assessed 2–7.5 months after treatment initiation. Pooled cure rates were estimated using random‐effects meta‐analysis. Subgroup analyses were performed for Old World (OWCL) and New World (NWCL) CL, and by Leishmania species. Results: Eighty‐three studies comprising 96 treatment arms and 4603 patients with OWCL and NWCL were included. Overall, study quality was moderate (per JBI checklist). MA, long regarded as standard of care in many countries, had a pooled cure rate of 59% (95% CI 52%–66%). Higher rates were observed with L‐AmB (77%; 95% CI 56%–90%), followed by miltefosine (75%; 95% CI 69%–81%), itraconazole (70%; 95% CI 65%–76%), and fluconazole (62%; 95% CI 16%–93%). Lower rates were obtained with pentamidine (55%; 95% CI 42%–67%) and ketoconazole (36%; 95% CI 7%–82%). Species‐ and region‐specific sub‐analyses indicated miltefosine highly effective for OWCL (particularly L. major ) and NWCL ( L. braziliensis , L. guyanensis , L. panamensis ). Head‐to‐head comparisons of miltefosine and MA showed no statistically significant difference. L‐AmB was similarly effective in NWCL (particularly L. braziliensis ), with lack of evidence for other species. Conclusions: Systemic treatment options for CL show variable efficacy. Despite the promising cure rates for miltefosine and L‐AmB, comparative evidence remains insufficient to support therapy recommendations. Confirmation in adequately powered, high‐quality RCTs, ideally stratified by species, is warranted to strengthen the evidence base.
- 8 September 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Open AccessSystemic treatment of cutaneous leishmaniasis: A systematic review and meta‐analysis
Background: Cutaneous leishmaniasis (CL) is increasingly reported in previously non‐endemic European countries. Although often self‐limiting or amenable to topical therapy, systemic treatment is indicated in specific situations. Evidence guiding systemic therapies remains limited and heterogeneous. Objectives: This systematic review and meta‐analysis aimed to synthesize available evidence on systemic treatment regimens for CL. Methods: MEDLINE/PubMed and Embase were searched for clinically and/or parasitologically confirmed CL receiving systemic monotherapy with meglumine antimoniate (MA), miltefosine, azoles, pentamidine, or liposomal amphotericin B (L‐AmB) until February 2026. Primary outcome was clinical cure assessed 2–7.5 months after treatment initiation. Pooled cure rates were estimated using random‐effects meta‐analysis. Subgroup analyses were performed for Old World (OWCL) and New World (NWCL) CL, and by Leishmania species. Results: Eighty‐three studies comprising 96 treatment arms and 4603 patients with OWCL and NWCL were included. Overall, study quality was moderate (per JBI checklist). MA, long regarded as standard of care in many countries, had a pooled cure rate of 59% (95% CI 52%–66%). Higher rates were observed with L‐AmB (77%; 95% CI 56%–90%), followed by miltefosine (75%; 95% CI 69%–81%), itraconazole (70%; 95% CI 65%–76%), and fluconazole (62%; 95% CI 16%–93%). Lower rates were obtained with pentamidine (55%; 95% CI 42%–67%) and ketoconazole (36%; 95% CI 7%–82%). Species‐ and region‐specific sub‐analyses indicated miltefosine highly effective for OWCL (particularly L. major ) and NWCL ( L. braziliensis , L. guyanensis , L. panamensis ). Head‐to‐head comparisons of miltefosine and MA showed no statistically significant difference. L‐AmB was similarly effective in NWCL (particularly L. braziliensis ), with lack of evidence for other species. Conclusions: Systemic treatment options for CL show variable efficacy. Despite the promising cure rates for miltefosine and L‐AmB, comparative evidence remains insufficient to support therapy recommendations. Confirmation in adequately powered, high‐quality RCTs, ideally stratified by species, is warranted to strengthen the evidence base.
- Open Access
- 7 September 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Congenital Palmoplantar Keratoderma and Woolly Hair in a Child: A Quiz
- 7 September 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessCongenital Palmoplantar Keratoderma and Woolly Hair in a Child: A Quiz
- Open Access
- 24 February 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e182644
Diagnostics and treatment of cutaneous and mucocutaneous Leishmania infections: expert recommendations
Cutaneous and mucosal/mucocutaneous Leishmania infections may present with very different clinical signs depending on the involved species, the site of infection and the immune status of the host. Leishmania species are intracellular protozoan pathogens transmitted by phlebotomine sand flies, of which over 20 species infecting humans have been described. Leishmania infections are rather common, with an estimated number of one million new cases per year worldwide. The countries with the highest incidence of cutaneous leishmaniasis cases are Afghanistan, Algeria, Brazil, Colombia, Iraq, Libya, Pakistan, Peru, Syria, and Tunisia, while most mucocutaneous cases occur in Bolivia, Brazil, Ethiopia, and Peru. The disease is also endemic in all Southern European countries, with approximately 700 autochthonous human cases reported each year and many more asymptomatic infections. Central Europe is considered non-endemic for the disease; however, epidemiological patterns are affected by travel habits, migration, globalization, and climate change. This review focuses on the diagnostic procedures and treatment options for cutaneous and mucocutaneous Leishmania infections.
- 24 February 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e182644
Open AccessDiagnostics and treatment of cutaneous and mucocutaneous Leishmania infections: expert recommendations
Cutaneous and mucosal/mucocutaneous Leishmania infections may present with very different clinical signs depending on the involved species, the site of infection and the immune status of the host. Leishmania species are intracellular protozoan pathogens transmitted by phlebotomine sand flies, of which over 20 species infecting humans have been described. Leishmania infections are rather common, with an estimated number of one million new cases per year worldwide. The countries with the highest incidence of cutaneous leishmaniasis cases are Afghanistan, Algeria, Brazil, Colombia, Iraq, Libya, Pakistan, Peru, Syria, and Tunisia, while most mucocutaneous cases occur in Bolivia, Brazil, Ethiopia, and Peru. The disease is also endemic in all Southern European countries, with approximately 700 autochthonous human cases reported each year and many more asymptomatic infections. Central Europe is considered non-endemic for the disease; however, epidemiological patterns are affected by travel habits, migration, globalization, and climate change. This review focuses on the diagnostic procedures and treatment options for cutaneous and mucocutaneous Leishmania infections.
- Open Access
- 7 October 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv44491
Self-healing Juvenile Cutaneous Mucinosis: an Extremely Rare and Alarming but Harmless Cutaneous Disease of Childhood
- 7 October 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv44491
Open AccessSelf-healing Juvenile Cutaneous Mucinosis: an Extremely Rare and Alarming but Harmless Cutaneous Disease of Childhood
- Open Access
- 10 October 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (10) , e8043
Benign cephalic histiocytosis in a 2‐year‐old boy with an inconspicuous clinical presentation at onset
Key Clinical Message: We report on a 2‐year‐old boy whose initially inconspicuous skin lesions later on evolved into a typical clinical presentation of benign cephalic histiocytosis (BCH). The diagnosis of BCH can often be made on clinical grounds without the need for an extensive diagnostic work‐up. Given the benign and self‐limited course of the disease treatment is not required and the clinical management can be limited to a watchful waiting approach.
- 10 October 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (10) , e8043
Open AccessBenign cephalic histiocytosis in a 2‐year‐old boy with an inconspicuous clinical presentation at onset
Key Clinical Message: We report on a 2‐year‐old boy whose initially inconspicuous skin lesions later on evolved into a typical clinical presentation of benign cephalic histiocytosis (BCH). The diagnosis of BCH can often be made on clinical grounds without the need for an extensive diagnostic work‐up. Given the benign and self‐limited course of the disease treatment is not required and the clinical management can be limited to a watchful waiting approach.
- Open Access
- 28 June 2023
- Published by Wiley
Benign cephalic histiocytosis in a 2-year-old boy with an inconspicuous clinical presentation at onset
Benign cephalic histiocytosis in a 2-year-old boy with an inconspicuous clinical presentation at onsetSandra Osorio1, Lucie Harpain1, Karin Jahn-Bassler2, Adrian Tanew2, Sonja Radakovic11 Medical University of Vienna, Department of Dermatology, Vienna, Austria2 Private Practice, Vienna, Austria
- 28 June 2023
- Published by Wiley
Open AccessBenign cephalic histiocytosis in a 2-year-old boy with an inconspicuous clinical presentation at onset
Benign cephalic histiocytosis in a 2-year-old boy with an inconspicuous clinical presentation at onsetSandra Osorio1, Lucie Harpain1, Karin Jahn-Bassler2, Adrian Tanew2, Sonja Radakovic11 Medical University of Vienna, Department of Dermatology, Vienna, Austria2 Private Practice, Vienna, Austria
- 22 February 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (7) , E865-E867
Complete resolution of recalcitrant disseminated cutaneous warts after partial irradiation with photodynamic therapy via presumed stimulation of a systemic immune response: A retrospective analysis of 18 cases
- 22 February 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (7) , E865-E867
Complete resolution of recalcitrant disseminated cutaneous warts after partial irradiation with photodynamic therapy via presumed stimulation of a systemic immune response: A retrospective analysis of 18 cases